Anticipate generic drug launch
Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Find generic entry opportunities
Drug patents …
… from Kazakhstan to Kalamazoo
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Locally administrable therapeutic composition for inflammatory disease|
|Abstract:||This invention relates to a locally administrable therapeutic composition for inflammatory disease which is characterized by comprising benzoylphenylacetic acid of the formula ##STR1## (wherein R is a hydrogen or halogen atom), or a salt thereof, or the hydrate of said acid or salt, as active ingredient. An ophthalmic composition according to the invention can treat effectively inflammatory eye disease by topical application, is not an irritant to the eye, and has a superior effect to conventional drugs of the same or similar type. The aqueous composition prepared in accordance with this invention has excellent stability and can be used advantageously as a nasal or otic composition as well as an ophthalmic one in the treatment of inflammatory otic or nasal disease.|
|Inventor(s):||Ogawa; Takahiro (Nishinomiya, JP), Kuribayashi; Yoshikazu (Kobe, JP), Ushio; Kazumichi (Nishinomiya, JP), Ohtori; Akira (Nara, JP)|
|Assignee:||Senju Pharmaceutical Co., Ltd. (Osaka, JP) A. H. Robins Company, Incorporated (Richmond, VA)|
Patent Claim Types:|
see list of patent claims
|Use; Composition; Compound; Formulation;|
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|Japan||63-16683||Jan 27, 1988|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Australia||609932||<disabled in preview>|
|Canada||1325382||<disabled in preview>|
|Germany||68902649||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.